Drug Profile
Niclosamide intramuscular depot - Daewoong Pharmaceutical/ Institut Pasteur Korea
Alternative Names: DWRX 2003; Niclosamide - Daewoong Pharmaceutical/ Institut Pasteur Korea; Niclosamide IM Depot - Daewoong Pharmaceutical/ Institut Pasteur KoreaLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Daewoong Pharmaceutical; Institut Pasteur Korea
- Developer Daewoong Pharmaceutical
- Class Anthelmintics; Anti-inflammatories; Antibacterials; Antineoplastics; Antivirals; Benzamides; Chlorophenols; Nitrobenzenes; Skin disorder therapies; Small molecules
- Mechanism of Action Autophagy stimulants; Mitochondrial oxidative phosphorylation uncouplers; MTOR protein inhibitors; Notch signalling pathway inhibitors; STAT3 transcription factor inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II COVID 2019 infections
- Preclinical Influenza virus infections
- No development reported Lung disorders
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Lung-disorders in South Korea (IM, Controlled release)
- 28 Nov 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in Australia (IM, Controlled release)
- 28 Oct 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in India (IM, Controlled release)